SecBot SecBot
144 ·Filed May 18, 2026

ARTV

Artiva Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001736819-26-000003
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

No actionable trading signal. The filing confirms a mechanical tax-withholding-sale, a routine post-vesting event. The insider continues to hold a significant number of restricted shares. Monitor for any future open-market filings (e.g., Rule 10b5-1 plan amendments) that might signal a change in insider sentiment.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.55
T+0 close · May 18, 2026 · via day close
Latest settled
+32.16%
T+60 · $11.30
Vs SPY
+25.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $8.55entry
  2. T+1 · 6mo ago −8.30%α −9.34% · $7.84
  3. T+5 · 6mo ago −10.76%α −13.06% · $7.63
  4. T+20 · 5mo ago +16.26%α +15.27% · $9.94
  5. T+60 · 3mo ago +32.16%α +25.87% · $11.30

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Artiva Biotherapeutics (ARTV) director Christopher Horan filed a Form 144 to sell 7,500 shares (~$69K estimated value) as a sell-to-cover transaction for tax withholding on RSU vesting. This is a routine, non-discretionary sale tied to equity compensation, not a signal of insider bearishness.

Key Facts

  • Form 144 filed by director Christopher Horan for 7,500 common shares.
  • Sale is explicitly described as 'sell-to-cover' for taxes on RSU vesting.
  • Shares were acquired on 5/15/2026 via RSU vesting under issuer's registered plan.
  • Estimated aggregate market value: ~$69,150 (based on recent market price).
  • Proposed sale date: 5/18/2026, same day as filing.
  • Selling broker: Morgan Stanley Smith Barney LLC.

Financial Impact

Proceeds ~$69K, trivial relative to company's $242M market cap and insider's likely holdings.

dilution

Risk Factors

  • None from this filing itself, the sale is mandated by tax withholding, not discretion.
  • High insider ownership concentration remains a positive governance factor.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001736819-26-000003
Document: 0001736819-26-000003-index.html0001736819-26-000003
Document: 0001736819-26-000003.txt0001736819-26-000003

Track record

33 reports on ARTV

Performance horizon

11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
  2. Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
  3. Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
  4. Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
  5. Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
  6. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  7. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
  10. Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
Showing 10 of 33

US Market Status

Market Closed · Opens in 8h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026